A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Clinical trial NCT04486781 · UNKNOWN

Trial details

NCT number: NCT04486781
Sponsor: Vasgene Therapeutics, Inc
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Urothelial Carcinoma

Start date: 2020-08-14
Primary completion: 2025-12-31
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.